Product Name

  • Name

    (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl)allylamine dihydrochloride

  • EINECS
  • CAS No. 60525-15-7
  • Density 1.286g/cm3
  • Solubility
  • Melting Point
  • Formula C16H17BrN2•2ClH
  • Boiling Point 412.8°C at 760 mmHg
  • Molecular Weight 390.15
  • Flash Point 203.4°C
  • Transport Information
  • Appearance
  • Safety Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects: ataxia, diarrhea, fasciculations, hypermotility, jaundice. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of Br−, NOx, and HCl. See also ZIMELIDINE.
  • Risk Codes
  • Molecular Structure Molecular Structure of 60525-15-7 ((Z)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl)allylamine dihydrochloride)
  • Hazard Symbols
  • Synonyms (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridyl)allylamine dihydrochloride
  • PSA 16.13000
  • LogP 4.63940

Zimeldine hydrochloride Chemical Properties

EINECS of Zimeldine hydrochloride (CAS NO.60525-15-7): 262-279-7 
Empirical Formula: C16H19BrCl2N2
Molecular Weight: 390.1455 g/mol
Flash Point: 203.4 °C
Enthalpy of Vaporization: 66.55 kJ/mol
Boiling Point: 412.8 °C at 760 mmHg
Vapour Pressure: 5.05E-07 mmHg at 25 °C
Structure of Zimeldine hydrochloride (CAS NO.60525-15-7):
                           
IUPAC Name: (Z)-3-(4-Bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-aminedihydrochloride
Canonical SMILES: CN(C)CC=C(C1=CC=C(C=C1)Br)C2=CN=CC=C2.Cl.Cl
Isomeric SMILES: CN(C)C/C=C(/C1=CC=C(C=C1)Br)\C2=CN=CC=C2.Cl.Cl
InChI: InChI=1S/C16H17BrN2.2ClH/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13;;/h3-10,12H,11H2,1-2H3;2*1H/b16-9-;;
InChIKey: CXGURXWCQYHDIR-ULPVBNQHSA-N

Zimeldine hydrochloride Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LDLo oral 80mg/kg (80mg/kg)   Acta Pharmaceutica Suecica. Vol. 20, Pg. 295, 1983.
dog LD50 intravenous 57mg/kg (57mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1833, 1983.
dog LD50 oral 271mg/kg (271mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1833, 1983.
man TDLo oral 36mg/kg (36mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD British Medical Journal. Vol. 287, Pg. 1672, 1983.
mouse LD50 intraperitoneal 84400ug/kg (84.4mg/kg)   Acta Pharmaceutica Suecica. Vol. 20, Pg. 295, 1983.
mouse LD50 intravenous 27700ug/kg (27.7mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1833, 1983.
mouse LD50 oral 341mg/kg (341mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1833, 1983.
mouse LD50 subcutaneous 154mg/kg (154mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1833, 1983.
rabbit LD50 intravenous 50800ug/kg (50.8mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE		 Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1833, 1983.
rabbit LD50 oral 300mg/kg (300mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1833, 1983.
rat LD50 intraperitoneal 99800ug/kg (99.8mg/kg)   Acta Pharmaceutica Suecica. Vol. 20, Pg. 295, 1983.
rat LD50 intravenous 45800ug/kg (45.8mg/kg) SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Kiso to Rinsho. Clinical Report. Vol. 17, Pg. 1833, 1983.
rat LD50 oral 844mg/kg (844mg/kg)   Acta Pharmaceutica Suecica. Vol. 20, Pg. 295, 1983.
rat LD50 subcutaneous 227mg/kg (227mg/kg)   Acta Pharmaceutica Suecica. Vol. 20, Pg. 295, 1983.
women TDLo oral 12mg/kg/6D-I (12mg/kg) PERIPHERAL NERVE AND SENSATION: FASCICULATIONS
BEHAVIORAL: ATAXIA		 Human Toxicology. Vol. 3, Pg. 141, 1984.
women TDLo oral 36mg/kg/9D-I (36mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED"		 British Medical Journal. Vol. 287, Pg. 1181, 1983.

 

Zimeldine hydrochloride Safety Profile

Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects: ataxia, diarrhea, fasciculations, hypermotility, jaundice. An experimental teratogen. Experimental reproductive effects. When heated to decomposition Zimeldine hydrochloride (CAS NO.60525-15-7) emits toxic fumes of Br−, NOx, and HCl. See also ZIMELIDINE.

Zimeldine hydrochloride Specification

 Zimeldine hydrochloride , its cas register number is 60525-15-7. It also can be called Zimeldine ; Zimelidine hydrochloride ; and Zelmid .

Related Products

Hot Products

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View